Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 133

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 133
---
Ivf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient’s
needs. These technologies include:

| ● | Preimplantation Genetic Screening (“PGS”): PGS is                                                                                   
 used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too 
 few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid   
 embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf   
 by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.                                           |

| ● | Next-Generation Sequencing (“NGS”): NGS is a high-throughput                                                                             
 technology for determining the sequence of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”) to study                            
 genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by         
 using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands 
 of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and        
 data output.                                                                                                                             |

| ● | Preimplantation Genetic Diagnosis (“PGD”): Similar                                                                                    
 to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process more enhanced than PGS since it scans for      
 individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, such as sickle cell disease or cystic 
 fibrosis, where carrier status has been documented in each of the parents. By using this technique, physicians are able to check      
 the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage and this technology can help      
 women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt     
 to screen for healthy embryos ahead of time.                                                                                          |

<div align='center'>79</div>

Well Established Brand with Reliable Reputation

The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own